MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma

SUMMARY Rationale: Esophageal cancer (EC) is the seventh most frequently diagnosed cancer and the sixth leading cause of cancer-related death worldwide. As a result of the late onset of symptoms, most patients with EC present in an advanced stage with a corresponding poor prognosis. Poor disease outcome after surgery alone (5-yr overall survival between 25-40%) prompted many researchers to explore neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant or perioperative chemotherapy (nCT/pCT) approaches. nCRT has led to pathological complete response (pCR) rate in squamous cell EC of almost 50%. Pa

Trial Details

NCT ID
NCT07359417
Phase
PHASE1
Sponsor
UMC Utrecht
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Radiation: MRI guided radiotherapy
Locations (sample)
  • Utrecht, Utrecht, Netherlands|52.09083,5.12222

Key Eligibility Criteria

  • In order to be eligible for this study, a subject must meet all of the following criteria:
  • Histologically confirmed squamous cell carcinoma of the esophagus or GE- junction (Siewert I/II)
  • Potentially resectable, locally advanced esophageal tumor (cT1bN+, cT2-3, N0-3, M0) based on standard primary staging by EUS and 18F-FDG PET-CT
  • Scheduled to receive neoadjuvant chemoradiotherapy according to CROSS-regimen: weekly administration of carboplatin and paclitaxel for 5 weeks and …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →